semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervix Uteri--Diseases Adult female subjects (age 18 years or older) Performance status ECOG 0-1 All patients must have cervical biopsies demonstrating high-grade cervical dysplasia All patients must have a satisfactory colposcopy with visualization of the entire squamo-columnar junction All patients must be candidates for a cervical conization procedure or LEEP procedure The patient is able and willing to comply with study procedures, and signed and dated informed consent is obtained before any study-related procedure is performed Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus At least six weeks must have elapsed from any prior chemotherapy, radiation therapy or immunotherapy Patients must have adequate Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl. Platelets greater than or equal to100, 000/mcl. Hemoglobin > 9 gm/dL  The patient is lactating or pregnant The colposcopy is inadequate; the entire transformation zone is not visualized and endocervical curettage is positive for high-grade dysplasia Clinical concern for invasive cervical cancer Patients must not have received any prior oncology vaccine therapy Intercurrent medical illnesses that would impair patient tolerance to participation Any concurrent medical condition requiring the use of systemic steroids is not permitted (the use of inhaled or topic steroids is permitted) Concurrent treatment with chemotherapy, radiation therapy or immunotherapy for intercurrent illnesses Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Intraepithelial Neoplasia Patients aged ≥ 18 and ecog performance status ≤ 1 2. Patients with a diagnosis of high-grade cervical intraepithelial neoplasia or initially invasive cervical cancer (histological results ≥ CIN2 + and ≤ Ia1 according to the FIGO staging of cervical cancer) 3. No fever at the time of vaccination 4. No previous HPV vaccination 5. Ability to understand and write Italian 6. Signed informed and privacy consent  Patients enrolled in other clinical studies 2. History of allergic reaction or serious adverse events to previous vaccinations 3. Positive pregnancy test at the time of vaccination 4. Patient in treatment with immunosuppressive therapy 5. Subjects who received immunoglobulins or blood products in 3 months prior to vaccination. 6. Thrombocytopenia or any other clotting disorder that may lead to bleeding as a result of intramuscular administration 7. Clinical contraindicating the surgical act of conization 8. ECOG performance status ≥2
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Menopause Surgical Estrogen Deficiency Adiposity Follicle-Stimulating Hormone Deficiency Hormone Deficiency Healthy female Ages 18-50 y Planning to have either a laparoscopic bilateral oophorectomy or a laparoscopic unilateral oophorectomy (which would result in no remaining ovaries) Are willing to drink heavy water (2H2O) over an 8-week period Medically cleared for participation in the study by OB/GYN and Medical Investigator Are willing to have blood and fat tissue stored for future use  Meet either of the following Have all 3 of the major menopause-related symptoms [hot flashes, mood swings, insomnia (trouble sleeping)] Have 2 of the major menopause-related symptom combinations [hot flashes and mood swings, or hot flashes and insomnia (trouble sleeping)] Unstable weight in the last 3 months [gain or loss >7 lb (or 3.2 kg)] History of clinically diagnosed diabetes or a fasting blood glucose >126 mg/dL Chronic use of systemic glucocorticoids, antipsychotic/antidepressant medications, thiazolidinediones and other medications that cause clinically significant weight gain, weight loss or are known to make changes in fat cell number/size * Previous bariatric surgery (or other surgeries) for obesity or weight loss (< 3 years ago) Use of over the counter or prescription weight loss products History of metabolic diseases (other than diabetes) History of neurological disease
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-66.0,  Cervical Cancer Screening Cervical Cancer women from 30 to 66 years old women living in french territorial division 37 ("Indre-et-Loire") women with a mobile phone in database women who do not perform a pap smear in the last 4 years women who do not answer to a first "invitation" letter to perform a pap smear  STOP SMS HPV cervical pathology during treatment Hysterectomy including cervix
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 9.0-45.0,  Papillomavirus Infections Participant is a Chinese female judged to be in good physical health based on medical history and physical examination Not a woman of childbearing potential (WOCBP) or if of WOCBP, has not had sex with males or has had sex with males and used effective contraception as defined in Appendix 2 since the first day of participant's last menstrual period through Day 1. And the participant understands and agrees that during the Day 1 through Month 7 period, she should not have sexual intercourse with males without effective contraception, and that the use of the rhythm method, withdrawal, and emergency contraception are not acceptable methods Has a lifetime history of 0 to 4 male and/or female sexual partners at the time of enrollment. Male partner is defined as someone with whom the participant has penile penetrative sexual intercourse. Female partner is defined as someone who has contacted, either by penetrative (with fingers or other objects) or non-penetrative means, the participant's genitalia during sexual activity  Known allergy to any vaccine component, including aluminum, yeast, or (nuclease, Nycomed™). An allergy to vaccine components is defined as an allergic reaction that met the for serious adverse event History of severe allergic reaction (e.g. swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Has a fever (defined as an axillary temperature ≥37.1°C) within 24 hours prior to the Day 1 vaccination Has any history of abnormal Pap test showing squamous intraepithelial lesion (SIL) or atypical squamous cells undetermined significance (ASC-US), atypical squamous cells cannot HSIL (ASC-H), atypical glandular cells, or biopsy showing cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ or cervical cancer History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer History of a positive test for HPV Currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  ASC-US Human Papilloma Virus female patients aged between 30-65 who were undergoing smear tests with the aim of control body mass index (BMI) lower than 35 Participants did not have any chronic diseases  Patients taking B12 and folate supplement due to mix type anemia patients taking active vitamin B12 and folate-containing vitamin supplements pregnant women women with other cervical intraepithelial lesions such as low grade squamous intraepithelial lesion (LGSIL), high grade squamous intraepithelial lesion (HGSIL) or high grade squamous intraepithelial lesion can not be excluded (ASC-H) in smear patients with cervical cancer diagnosis patients who were operated due to cervical cancer patients who had HPV vaccine patients with a diagnosis that can inhibit B12 and folate absorption in gastro-intestinal tract vegetarians
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  ASC-US LSIL Patients with persistent (>6 month period) ASC-US/LSIL determined by cervical cytology at study entry (ThinPrep with imaging) 2. Patients whose cytologic samples are persistent (>6 month period) HPV16+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test or other FDA-approved HPV genotyping test at study entry. Co-infections with HPV types other than HPV16 are permissible for study entry. 3. Age ≥ 19 years 4. Baseline Eastern Cooperative Oncology Group 5. Patients must have adequate organ function at the time of enrollment as defined by the following parameters White blood cell count > 3,000 Absolute lymphocyte number > 500 Absolute neutrophil count > 1,000 Platelets > 90,000 Hemoglobulin > 9 Total bilirubin <3 X the institutional limit of normal AST(SGOT)/ALT(SGPT) <3 X the institutional limit of normal Creatinine < 2.5X the institutional limit of normal 6. Women of child-bearing potential must agree to use two forms of contraception (hormonal and barrier) prior to study entry and for 3 months after study completion. 7. Ability to understand and the willingness to sign a written informed consent document. 8. Subject is able to adhere to the study visit schedule and other protocol requirements  Patients with ASC-US/LSIL determined by cervical cytology at study entry that are HPV16 negative. 2. Histologic evidence of CIN2+ 3. Patients with a diagnosis of immunosuppression or prolonged, active use of immunosuppressive medications such as steroids. 4. Prior vaccination with any HPV antigen (prophylactic or therapeutic). 5. Patients who are receiving any other investigational agents within 28 days prior to the first dose. 6. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 7. Patients with a history of autoimmune disease such as multiple sclerosis, exclusive of a history of thyroiditis, psoriasis, Sjrogen's, or inflammatory bowel disease. 8. Patients with a history of allergic reactions attributed to compounds used in agent preparation. 9. Patients who are pregnant or breast feeding. 10. Patient with active or chronic infection of HIV, HCV, or HBV. 11. Patients who have had a prior LEEP or cervical conization procedure. 12. History of prior malignancy permitted if patient has been disease free for ≥ 5 years; however individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled. 13. Inability to understand or unwillingness to sign an informed consent document
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Meet at least 4 American College of Rheumatology for systemic lupus erythematosus (SLE) or rheumatologist diagnosis of SLE Over the preceding 3 years, at least 1 hospitalization or ED visit related to lupus OR at least 1 rheumatology appointment no-show or same-day cancellation Receive their primary care at BWH  Non-English speaker
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  High-Grade Squamous Intraepithelial Lesions Patients followed within the CHU Brugmann Hospital (no private practices) HSIL lesions confirmed by anatomopathologic analysis on cervical biopsies or cone specimen without evidence of invasive lesions  Invasive lesions
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Choroidal Melanoma Indeterminate Lesions of Eye Have been clinically diagnosed with primary CM or IL at the time of entry to a previous Aura Biosciences sponsored clinical trial Have received AU-011 or assigned to an observation cohort in a previous Aura sponsored clinical trial  None
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Precancerous Lesions Conization High Grade Intraepithelial Neoplasia Uterine Cervical Cancer Fertility Pregnancy Human Papillomavirus Infection Accepting conization in the study center Aged 18 years or older  Not meeting any of the
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaccine Refusal Parents of children 2-18 years old  None
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Breast Cancer Contraceptive Usage Sexually Transmitted Diseases -Scheduled to leave jail within 3 days  not actively intoxicated not show severe psychological distress
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Papillomavirus Infections Healthy Has not had sex with males or has had sex with males and used effective contraception with no failures since the first day of the participant's last menstrual period through Day 1 Agrees to use effective contraception if has sex with a male partner during study Has had sexual intercourse with male partners, and has had 1 to 4 male and/or female sexual partners  History of a positive test for HPV History of an abnormal Pap test result showing ASC-US, atypical squamous cells - cannot HSIL (high grade squamous intraepithelial lesion [(ASC-H)], low-grade squamous intraepithelial lesion (LSIL), HSIL), or atypical glandular cells History of an abnormal cervical biopsy result showing CIN, adenocarcinoma in situ or cervical cancer History of or clinical evidence at the Day 1 gynecologic examination of HPV-related anogenital diseases (e.g., genital warts, VIN, VaIN, AIN, vulvular cancer, vaginal cancer or anal cancer Does not have an intact cervix uteri or has more than one cervix uteri Is pregnant Known allergy to any vaccine component, including aluminum, yeast, or Benzonase™ (nuclease, Nycomed™ [used to remove residual nucleic acids from this and other vaccines]) History of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension or shock) that required medical intervention Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Cervical Cancer Pathological Screening Smear Women followed for a cervical pathology requiring endocervical curettage AGC type (glandular cell atypia) with positive HPV test Frottis ASC-H, LSIL, ASCUS HPV + with non-contributive colposcopy (ZT3)  Pregnant woman Women under the age of 25 or over 65 Stenosis of the neck complete or tight not allowing the possible insertion of a curette (inadequate size cervical orifice and material) Presence of a vaginal lesion on colposcopic examination
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Distal Femur Fracture Age 18 years and older Diagnosis of a distal femur fracture type OTA/AO classification 33-A, -B, -C uni or bilateral low or high energy trauma Open or closed fractures Surgical treatment with the VA-LCP DF, LISS DF, LCP DF Available radiographical documentation, beginning with the injury radiographs, ending with the documented healing or any documented failure with or without revision surgery (up to a maximum follow-up of 1 year
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  HIV/AIDS Cervical Dysplasia HIV Infections Kenyan women who present for a cervical cancer screening at cancer screening clinics at MTRH or Webuye and living in or within 30 km of the respective clinic at the time of informed consent 2. Between the ages of 18 -45 years old at the time of informed consent 3. Ability to provide written informed consent and HIPAA authorization 4. Must have a normal VIA 5. Must be willing and able to come to the clinic for visits and return for a 4 year follow-up visit  History of an abnormal VIA or Pap smear 2. Diagnosis of CIN or cervical cancer 3. Signs or symptoms of a sexually transmitted infection (STI) 4. Women who are currently pregnant 5. Inability to understand and provide written informed consent due to a mental or physical disability, or a medical illness that has rendered the patient unable to understand consent or attend quarterly visits